On Friday, Axsome Therapeutics Inc (NASDAQ: AXSM) was -4.31% drop from the session before settling in for the closing price of $97.37. A 52-week range for AXSM has been $56.66 – $105.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 88.16%. When this article was written, the company’s average yearly earnings per share was at -3.96%. With a float of $39.56 million, this company’s outstanding shares have now reached $47.35 million.
Let’s determine the extent of company efficiency that accounts for 545 employees. In terms of profitability, gross margin is 90.55%, operating margin of -90.84%, and the pretax margin is -91.97%.
Axsome Therapeutics Inc (AXSM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Axsome Therapeutics Inc stocks. The insider ownership of Axsome Therapeutics Inc is 18.41%, while institutional ownership is 79.07%. The most recent insider transaction that took place on Sep 11 ’24, was worth 1,005,871. In this transaction Director of this company sold 11,016 shares at a rate of $91.31, taking the stock ownership to the 10,002 shares. Before that another transaction happened on Sep 11 ’24, when Company’s Director proposed sale 11,016 for $91.31, making the entire transaction worth $1,005,843.
Axsome Therapeutics Inc (AXSM) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -2.08 earnings per share (EPS) during the time that was less than consensus figure (set at -1.19) by -0.89. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.96% per share during the next fiscal year.
Axsome Therapeutics Inc (NASDAQ: AXSM) Trading Performance Indicators
You can see what Axsome Therapeutics Inc (AXSM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.54, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -1.44 in one year’s time.
Technical Analysis of Axsome Therapeutics Inc (AXSM)
Looking closely at Axsome Therapeutics Inc (NASDAQ: AXSM), its last 5-days average volume was 1.02 million, which is a jump from its year-to-date volume of 0.62 million. As of the previous 9 days, the stock’s Stochastic %D was 53.13%. Additionally, its Average True Range was 3.79.
During the past 100 days, Axsome Therapeutics Inc’s (AXSM) raw stochastic average was set at 63.92%, which indicates a significant increase from 37.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.79% in the past 14 days, which was higher than the 35.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $90.66, while its 200-day Moving Average is $82.58. However, in the short run, Axsome Therapeutics Inc’s stock first resistance to watch stands at $96.48. Second resistance stands at $99.79. The third major resistance level sits at $101.77. If the price goes on to break the first support level at $91.19, it is likely to go to the next support level at $89.21. Should the price break the second support level, the third support level stands at $85.90.
Axsome Therapeutics Inc (NASDAQ: AXSM) Key Stats
There are 48,462K outstanding shares of the company, which has a market capitalization of 4.32 billion. As of now, sales total 270,600 K while income totals -239,240 K. Its latest quarter income was 87,170 K while its last quarter net income were -79,350 K.
